MNKD
MannKindANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that the May 29 pediatric sBLA decision plus the FDA's release from the older pulmonary-malignancy PMR de-risk Afrezza, while INHALE-1 keeps a visible pediatric development path open beyond the near-term decision.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +16.9.
What can break
INHALE-1 data are not expected until late 2027, so the thesis has a long gap before the next meaningful clinical readout.
Momentum
71
Value
64
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.30 · Bull $7.25 · Bear $2.15
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.72
Why
Momentum71 · Δ7d +16.9
Value64 · Δ7d -0.0
Sentiment64 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
71
34% active weight
Current posture
7d trendImproving
Δ7d
+16.9
Δ21d
+37.3
Value
64
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.0
Sentiment
64
33% active weight
Current posture
7d trendImproving
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 71.3 / Value 64.3 / Sentiment 64.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.09B
Beta
0.84
Shares Out
307.07M
P/E (TTM)
60.7
P/S (TTM)
5.50
P/FCF (TTM)
39.77
Rev YoY
+17.2%
EPS YoY
-36.8%
Gross Margin
+78.5%
Op Margin
+18.8%
Net Debt
$92.38M
Current Ratio
3.29
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology